OVERVIEW

Advances in™ Acute Lymphoblastic Leukemia (ALL): Optimal Use and Sequencing of Novel Agents Across Lines of Care is organized by Physicians' Education Resource, LLC (PER).

Release Date: January 31, 2020
Expiration Date: January 31, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Advances in™ ALL: Optimal Use and Sequencing of Novel Agents Across Lines of Care is an online activity featuring expert commentary regarding current and emerging treatment for acute lymphoblastic leukemia (ALL). Elias Jabbour, MD, is a professor in the Department of Leukemia, Division of Cancer Medicine, at The University of Texas (UT) MD Anderson Cancer Center in Houston, Texas. During this online program, he answers important questions and offers his perspectives on the clinical management of pediatric and adult ALL in the frontline and relapsed/refractory (R/R) settings.

Benefits of Participating:
• Be better able to identify patients presenting with ALL.
• Refresh your knowledge on risk stratification in ALL.
• Learn about clinical data from ongoing studies.
• Be more confident in your clinical decisions for pediatric and adult patient populations with ALL.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Outline risk stratification strategies in ALL to help develop appropriate treatment plans through cytogenetic and immunophenotypic studies.
• Select novel therapeutic options in the frontline and R/R settings and optimize the selection and sequencing of treatment options.
• Summarize the role of emerging therapies for the management of ALL.
• Evaluate groups of patients who may be eligible for emerging ALL treatment approaches.